Psoralen

Psoralen at a Glance

Psoralen is the parent linear furanocoumarin — a coumarin fused to a furan ring in a straight-line (linear) geometry, formally furo[3,2-g]chromen-7-one. It is the structural template for the whole psoralen family: adding a methoxy group at one position gives bergapten (5-methoxypsoralen, 5-MOP), and at another gives xanthotoxin (8-methoxypsoralen, 8-MOP), the two derivatives that dominate clinical use.

Its defining property is phototoxicity. Psoralen slips flat between the base pairs of DNA and, when the skin (or a sample) is then exposed to ultraviolet A (UVA) light, forms covalent adducts and cross-links with DNA ^{1,2Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →Reference 2Bellani MA et al. · 2023Imaging the cellular response to an antigen tagged interstrand crosslinking agentView study →}. This single photochemical fact runs through everything the molecule is known for: it is why furanocoumarin-rich plant sap causes phytophotodermatitis on sunny skin, why psoralens are used deliberately, with metered UVA, in PUVA photochemotherapy for psoriasis and vitiligo ^{3,4Reference 3Racz E · 2015Phototherapy and photochemotherapy for psoriasisView study →Reference 4Vieyra-Garcia PA · 2021A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancerView study →}, and why psoralen is a standard laboratory reagent for cross-linking DNA and RNA ^{2Reference 2Bellani MA et al. · 2023Imaging the cellular response to an antigen tagged interstrand crosslinking agentView study →}.

The linear-versus-angular distinction is the point of this molecule. Linear psoralen can reach thymines on both strands and so forms DNA interstrand cross-links — a doubly damaging, strongly phototoxic lesion — whereas its angular isomer angelicin (isopsoralen) is geometrically limited to single-strand monoadducts ^{1Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →}. Psoralen occurs in Psoralea corylifolia (babchi/bakuchi) and across the carrot, rue, citrus and fig families ^{10,11Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}.

Linear vs. Angular: The Cross-Link That Defines Psoralen

The most important thing about psoralen is a matter of shape. Furanocoumarins come in two geometries — linear (psoralen, bergapten, xanthotoxin) and angular (angelicin) — and that geometry decides how dangerous the molecule is under UV light.

The photoreaction happens in two steps ^{1Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →}:

1. Intercalation, then a first UVA photon. In the dark, psoralen slides flat between DNA base pairs. A first photon of 320–400 nm UVA drives a [2+2] cycloaddition, forming a covalent monoadduct with a pyrimidine (usually thymine) at either the pyrone (3,4) or the furan (4’,5’) double bond.
2. A second UVA photon. A monoadduct sitting at the furan side still has a reactive pyrone double bond. In linear psoralens that second reactive site points across the helix at a thymine on the opposite strand, so a second photon converts a fraction of the monoadducts into a DNA interstrand cross-link (ICL) — a covalent staple joining the two strands ^{1Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →}.

Angular furanocoumarins cannot do step 2. In angelicin the two reactive double bonds are bent away from each other, so it is confined to monoadducts and is a far weaker photosensitiser ^{1Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →}. This is why the linear psoralens are the phototoxic, therapeutically exploited, and laboratory-useful members of the family, while the angular ones are comparatively mild.

An interstrand cross-link is one of the most cytotoxic lesions a cell can face: it blocks both DNA replication and transcription, is removed only by a complex, error-prone repair pathway, and readily triggers cell death ^{1Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →}. That single property is simultaneously the hazard (phytophotodermatitis, photocarcinogenicity) and the therapy (killing hyperproliferating skin cells) — the same molecular event, pointed at different ends.

Photochemotherapy (PUVA)

Psoralen’s established human role is PUVA — psoralen plus UVA — in which a psoralen is taken (or applied), then the skin is exposed to a metered UVA dose. Neither the drug nor the light does much alone; the therapeutic effect is the photochemistry between them ^{4,8Reference 4Vieyra-Garcia PA · 2021A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancerView study →Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. In routine dermatology the psoralen given is usually the analogue methoxsalen (8-MOP), with bergapten (5-MOP) and trioxsalen as alternatives ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}.

The controlled DNA damage translates into three clinical uses:

• Psoriasis and cutaneous T-cell lymphoma. Cross-link-induced DNA damage inhibits keratinocyte proliferation and drives apoptosis of keratinocytes, dendritic cells and infiltrating T cells, damping the Th1/Th17 inflammation of plaque psoriasis and clearing the malignant T-cell infiltrate of mycosis fungoides ^{3,5Reference 3Racz E · 2015Phototherapy and photochemotherapy for psoriasisView study →Reference 5McNeely W · 1998ReviewMcNeely W, Goa KL (1998). 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs. https://pubmed.ncbi.nlm.nih.gov/9806110/View study →}.
• Vitiligo. Here the goal is repigmentation rather than cell-killing: PUVA stimulates melanocyte proliferation, migration and melanogenesis in depigmented skin ^{4,6Reference 4Vieyra-Garcia PA · 2021A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancerView study →Reference 6Parsad D · 2006Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligoView study →}.
• Extracorporeal photopheresis (ECP). In graft-versus-host disease and cutaneous lymphoma, a patient’s leukocytes are treated with 8-MOP and UVA outside the body and reinfused, triggering apoptosis of the treated lymphocytes and an immunomodulatory response ^{7Reference 7Budde H et al. · 2023Extracorporeal photopheresis and the cellular mechanisms: effects of 8-methoxypsoralen and UVA treatment on red blood cells, platelets and reactive oxygen speciesView study →}.

PUVA is genuinely effective, but it is no longer first-line for psoriasis or vitiligo: narrowband UVB gives comparable results without the systemic drug, the strict light-avoidance regimen, or the long-term skin-cancer signal ^{4,6,12Reference 4Vieyra-Garcia PA · 2021A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancerView study →Reference 6Parsad D · 2006Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligoView study →Reference 12Archier E et al. · 2012ReviewCarcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature reviewView study →}.

What It's Used For

Psoralen is unusual for a compound page: almost all of its documented activity is light-dependent, and the clinical evidence largely attaches to its methoxylated analogues rather than to the parent molecule. What follows separates the genuine human-therapy signal from the (much thinner) claims for “dark,” non-photoactivated psoralen.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Scores reward the established photochemotherapy drug class while noting that the dosed molecule is usually 8-MOP, not the parent psoralen.

01Photochemotherapy (PUVA)Promising62%Decades of clinical PUVA/ECP for psoriasis, CTCL and GvHD; defined apoptosis mechanism ^{3,5,7,8Reference 3Racz E · 2015Phototherapy and photochemotherapy for psoriasisView study →Reference 5McNeely W · 1998ReviewMcNeely W, Goa KL (1998). 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs. https://pubmed.ncbi.nlm.nih.gov/9806110/View study →Reference 7Budde H et al. · 2023Extracorporeal photopheresis and the cellular mechanisms: effects of 8-methoxypsoralen and UVA treatment on red blood cells, platelets and reactive oxygen speciesView study →Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}

02DNA Cross-Linking Research ToolPromising56%Established lab reagent — psoralen forms photo-induced interstrand cross-links ^{1,2Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →Reference 2Bellani MA et al. · 2023Imaging the cellular response to an antigen tagged interstrand crosslinking agentView study →}

03Vitiligo RepigmentationPromising48%Established but now second-line to NB-UVB; melanocyte-stimulation mechanism ^{4,6Reference 4Vieyra-Garcia PA · 2021A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancerView study →Reference 6Parsad D · 2006Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligoView study →}

04Preclinical “Dark” BioactivityShaky26%In-vitro/animal anticancer, antimicrobial, bone signals from Psoralea extracts ^{10Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →}

Mechanisms

The first row is load-bearing: the interstrand cross-link — available only to the linear psoralens — is simultaneously the therapeutic effect and the toxic one.

Pharmacokinetics

The parent psoralen’s own clinical pharmacokinetics are poorly characterised; the well-studied member of the class is its analogue methoxsalen (8-MOP), and the numbers below are for that drug ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. Psoralens are inactive without UVA, so pharmacokinetics matter only insofar as they set the skin drug level at the moment of irradiation. A standard oral methoxsalen dose is 0.5–0.7 mg/kg given ~2 hours before UVA; peak serum concentrations of ~50–250 µg/L appear 1–2 hours after ingestion, and the serum half-life is short (~0.5–2 h) ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. Absorption is erratic — strongly affected by food and by formulation (liquid soft-gelatin capsules give higher, faster peaks than crystalline tablets) — and the drug undergoes high, variable first-pass metabolism, so inter-patient clearance ranges roughly 40–650 L/h ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. This variability is why patients with high clearance and low peak levels often respond less to PUVA, and why serum-level monitoring has been used to individualise dosing ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. Bergapten has similar kinetics; trioxsalen is poorly bioavailable orally ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}.

Clinical Trials

Human evidence is for the photochemotherapy drug class, not for isolated parent psoralen as a systemic medicine. PUVA (usually 8-MOP) is an established, extensively used treatment for psoriasis, cutaneous T-cell lymphoma and vitiligo, and 8-MOP/UVA photopheresis is established for GvHD ^{3,5,7,8Reference 3Racz E · 2015Phototherapy and photochemotherapy for psoriasisView study →Reference 5McNeely W · 1998ReviewMcNeely W, Goa KL (1998). 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs. https://pubmed.ncbi.nlm.nih.gov/9806110/View study →Reference 7Budde H et al. · 2023Extracorporeal photopheresis and the cellular mechanisms: effects of 8-methoxypsoralen and UVA treatment on red blood cells, platelets and reactive oxygen speciesView study →Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}; comparative trials increasingly favour narrowband UVB for psoriasis and vitiligo ^{6,12Reference 6Parsad D · 2006Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligoView study →Reference 12Archier E et al. · 2012ReviewCarcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature reviewView study →}. There are no modern trials of non-photoactivated psoralen as a stand-alone drug.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule inverts the usual caveat. The isolate is the evidence — PUVA and photopheresis use a defined, purified psoralen (in practice 8-MOP) at a measured dose and a metered light exposure, and the laboratory cross-linking work uses pure psoralen or its trimethyl derivatives ^{2,8Reference 2Bellani MA et al. · 2023Imaging the cellular response to an antigen tagged interstrand crosslinking agentView study →Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. The plant side is where the picture blurs: Psoralea corylifolia seed extracts carry psoralen together with isopsoralen (angelicin), bakuchiol, psoralidin and bavachinin, so the extract’s antibacterial, antioxidant and bone-protective signals — and its hepatotoxicity — cannot be pinned on psoralen alone ^{10,14Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →Reference 14Yang H et al. · 2026Meta-analysisEfficacy and hepatotoxicity of Psoralea corylifolia L.: a meta-analysis and machine learning assessment in postmenopausal osteoporosisView study →}. Dietary/occupational exposure (figs, celery, parsnip, rue sap) is a mixture of furanocoumarins, which is why phytophotodermatitis reflects total furanocoumarin load rather than any one molecule ^{11Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}.

Its Role in Plants

Furanocoumarins are phytoalexins — chemical defences. Plants of the carrot, rue and fig families synthesise psoralen from the simple coumarin umbelliferone: umbelliferone is prenylated and cyclised (via marmesin) to the furan-fused psoralen skeleton, which is then methoxylated to give bergapten and xanthotoxin. In the plant, the same UVA-activated DNA-cross-linking chemistry that makes psoralen a drug makes it a broad-spectrum toxin against insect herbivores and microbes: a caterpillar that eats furanocoumarin-laden foliage in daylight suffers photo-activated tissue damage, so the compounds deter feeding ^{1,11Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}. Concentrations rise in the plant on wounding and in the reproductive parts (seeds, fruit) it most needs to protect. These are plant-defence functions and should not be read as human pharmacology.

Prevalence in Nature

Psoralen occurs across four plant families: the carrot family (Apiaceae) — celery, parsnip, giant hogweed, angelica; the rue/citrus family (Rutaceae) — common rue and citrus peel oils; the fig family (Moraceae), where it was one of its first-recognised sources (hence the synonym ficusin); and the legume family (Fabaceae), most notably the seeds of Psoralea corylifolia (babchi/bakuchi, now Cullen corylifolium), the traditional Ayurvedic and Chinese medicinal seed that gives the molecule its name ^{10,11Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}. Furanocoumarin content varies widely with species, chemotype, plant part, wounding and season, and the parent psoralen is frequently a minor member of a furanocoumarin mixture dominated by its 5- and 8-methoxy derivatives ^{11Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}. Quantitative per-source figures for the parent compound specifically are sparsely reported — the phytophotodermatitis literature generally measures total furanocoumarins rather than psoralen alone ^{11Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}.

Discovery & Synthesis

Psoralen takes its name directly from the plant genus Psoralea: it was first isolated in the 1930s from the seeds of Psoralea corylifolia, the babchi/bakuchi seed long used in Ayurvedic and Chinese medicine for vitiligo and other skin conditions ^{10Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →}. The photochemotherapeutic idea is far older than the isolated molecule — furanocoumarin-bearing plants such as Ammi majus and Psoralea were used with sunlight to treat depigmented skin in ancient Egyptian and Indian practice, and psoralens have been “applied therapeutically since antiquity” ^{2,10Reference 2Bellani MA et al. · 2023Imaging the cellular response to an antigen tagged interstrand crosslinking agentView study →Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →}. The structure–activity work that defined the family — the linear-versus-angular geometry, the two-photon monoadduct-then-cross-link mechanism, and the shift to the better-tolerated methoxylated analogues (5-MOP, 8-MOP) for clinical PUVA — was worked out through the mid-to-late twentieth century ^{1,8Reference 1Grossweiner LI · 1984ReviewMechanisms of photosensitization by furocoumarinsView study →Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}. Manufacture today is largely by extraction from furanocoumarin-rich plant material and by chemical synthesis of the psoralen skeleton and its derivatives for pharmaceutical (methoxsalen, trioxsalen) and laboratory (trimethylpsoralen) use.

Patents: not yet researched.

Toxicity & Safety

Psoralen carries a moderate flag. In the dark it is of low acute oral toxicity, but under UVA it is a DNA cross-linking agent, and that photochemistry drives every one of its real hazards.

Safety at a Glance

⚠️ Moderate toxicityPhotosensitivity

• In the dark, low acute toxicity. Psoralen’s harms are almost entirely light-dependent — it is inactive without UVA.
• Phytophotodermatitis. Skin contact with furanocoumarin-rich sap (giant hogweed, rue, celery, parsnip, figs, wild parsnip) followed by sunlight causes burning, blistering and long-lasting pigmentation.
• Photocarcinogenicity with therapeutic PUVA. Long-term, high-cumulative PUVA raises squamous-cell skin-cancer risk in a strongly dose-dependent way; eye protection is required to avoid cataract.
• CYP3A4 inhibition. As a furanocoumarin, psoralen contributes to the mechanism-based CYP3A4 inhibition behind the grapefruit-juice/citrus drug-interaction effect.
• Psoralea corylifolia supplements. Babchi/bakuchi seed products carry a documented hepatotoxicity signal; source and dose matter.

Full Safety & Interactions Detail

Phytophotodermatitis. The commonest real-world harm. Furanocoumarins in plant sap penetrate skin, and subsequent UVA exposure triggers the same DNA-adduct/cross-link and singlet-oxygen chemistry as PUVA, producing a phototoxic (not allergic) dermatitis: burning, erythema and bullae in sun-exposed contact areas, often followed by prolonged hyperpigmentation. Giant hogweed, wild parsnip, celery, rue, figs and bergamot/citrus oils are classic culprits, and the reaction reflects the total furanocoumarin load of the exposure ^{11Reference 11Grosu Dumitrescu C et al. · 2024New insights concerning phytophotodermatitis induced by phototoxic plantsView study →}.

Photocarcinogenicity. The therapeutic use has a well-documented long-term cost. In the 30-year PUVA Follow-Up Study, the risk of squamous-cell carcinoma rose steeply with cumulative treatment — patients with 350–450 treatments had roughly a six-fold higher yearly SCC risk than those with fewer than 50, and the effect was far stronger when all tumours were counted; basal-cell risk rose much less ^{9Reference 9Stern RS; PUVA Follow-Up Study · 2012The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective studyView study →}. A systematic review likewise found PUVA to carry a greater cutaneous carcinogenic risk than narrowband UVB, informing session caps ^{12Reference 12Archier E et al. · 2012ReviewCarcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature reviewView study →}. Methoxsalen-plus-UVA is treated by regulators as a human carcinogen, and eye protection during and after dosing is standard to prevent psoralen-mediated cataract ^{9,12Reference 9Stern RS; PUVA Follow-Up Study · 2012The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective studyView study →Reference 12Archier E et al. · 2012ReviewCarcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature reviewView study →}.

Drug interactions. Furanocoumarins are mechanism-based (irreversible) inhibitors of CYP3A4 — the molecular basis of the grapefruit-juice interaction, in which bergamottin and dihydroxybergamottin are the archetypal inhibitors; psoralen belongs to the same inhibitory chemotype, so heavy furanocoumarin exposure can raise levels of CYP3A4-metabolised drugs ^{13Reference 13Akiyoshi T et al. · 2022Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activityView study →}. Because PUVA itself is a photosensitising treatment, concurrent photosensitising drugs compound the phototoxic risk.

Hepatotoxicity of Psoralea corylifolia supplements. Distinct from the photochemistry: babchi/bakuchi seed products (and related “bakuchiol” botanicals) have been associated with herb-induced liver injury. A meta-analysis and benefit–risk assessment of P. corylifolia found a real efficacy signal for bone disorders set against a measurable hepatotoxicity signal (raised ALT/AST), underscoring a narrow therapeutic window and dose dependence ^{14Reference 14Yang H et al. · 2026Meta-analysisEfficacy and hepatotoxicity of Psoralea corylifolia L.: a meta-analysis and machine learning assessment in postmenopausal osteoporosisView study →}; the furanocoumarins and other seed constituents are implicated ^{10Reference 10Chopra B et al. · 2013ReviewPsoralea corylifolia L. (Buguchi) — folklore to modern evidence: reviewView study →}.

Reproductive note (prose only). No dedicated reproductive-toxicity dataset exists for isolated psoralen; as a photo-genotoxic DNA-cross-linking agent it warrants caution, and systemic PUVA is generally avoided in pregnancy at the treatment level. Pregnancy and lactation decisions belong to the herb or product page where intake is decided, not to this molecule page. No comprehensive isolate repeat-dose package is characterised here beyond the photobiology and the Psoralea-supplement toxicology above.

Dosage

There is no dietary or supplemental dose for psoralen — plant/food exposure is incidental and the molecule does nothing without ultraviolet light. Its only defined human dosing is medical PUVA, and in practice the dosed drug is the analogue methoxsalen (8-MOP), timed to a controlled UVA exposure and supervised by a dermatologist ^{8Reference 8de Wolff FA · 1986Clinical pharmacokinetics of methoxsalen and other psoralensView study →}:

The UVA dose is individualised to skin type and phototoxic threshold, and cumulative exposure is capped because of the photocarcinogenicity above. These are established clinical figures for the psoralen drug class, not a personal recommendation.

References

1. Grossweiner LI (1984). Mechanisms of photosensitization by furocoumarins. National Cancer Institute Monograph. https://pubmed.ncbi.nlm.nih.gov/6397692/
2. Bellani MA, et al. (2023). Imaging the cellular response to an antigen tagged interstrand crosslinking agent. DNA Repair. https://pubmed.ncbi.nlm.nih.gov/37320956/
3. Racz E, Prens EP (2015). Phototherapy and photochemotherapy for psoriasis. Dermatologic Clinics. https://pubmed.ncbi.nlm.nih.gov/25412785/
4. Vieyra-Garcia PA, Wolf P (2021). A deep dive into UV-based phototherapy: mechanisms of action and emerging molecular targets in inflammation and cancer. Pharmacology & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/33316286/
5. McNeely W, Goa KL (1998). 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs. https://pubmed.ncbi.nlm.nih.gov/9806110/
6. Parsad D, Kanwar AJ (2006). Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. Journal of the European Academy of Dermatology and Venereology. https://pubmed.ncbi.nlm.nih.gov/16441626/
7. Budde H, et al. (2023). Extracorporeal photopheresis and the cellular mechanisms: effects of 8-methoxypsoralen and UVA treatment on red blood cells, platelets and reactive oxygen species. Vox Sanguinis. https://pubmed.ncbi.nlm.nih.gov/37401421/
8. de Wolff FA, Thomas TV (1986). Clinical pharmacokinetics of methoxsalen and other psoralens. Clinical Pharmacokinetics. https://pubmed.ncbi.nlm.nih.gov/3512141/
9. Stern RS; PUVA Follow-Up Study (2012). The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. Journal of the American Academy of Dermatology. https://pubmed.ncbi.nlm.nih.gov/22264671/
10. Chopra B, Dhingra AK, Dhar KL (2013). Psoralea corylifolia L. (Buguchi) — folklore to modern evidence: review. Fitoterapia. https://pubmed.ncbi.nlm.nih.gov/23831482/
11. Grosu Dumitrescu C, et al. (2024). New insights concerning phytophotodermatitis induced by phototoxic plants. Life (Basel). https://pubmed.ncbi.nlm.nih.gov/39202761/
12. Archier E, et al. (2012). Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. https://pubmed.ncbi.nlm.nih.gov/22512677/
13. Akiyoshi T, et al. (2022). Analysis of inhibition kinetics of three beverage ingredients, bergamottin, dihydroxybergamottin and resveratrol, on CYP2C9 activity. Drug Metabolism and Pharmacokinetics. https://pubmed.ncbi.nlm.nih.gov/34979453/
14. Yang H, et al. (2026). Efficacy and hepatotoxicity of Psoralea corylifolia L.: a meta-analysis and machine learning assessment in postmenopausal osteoporosis. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/42331197/

View all 14 references▾